FDA Approves Migraine Treatments from AbbVie and IntelGenx

The FDA has expanded the indication of AbbVie’s Qulipta (atogepant) to prevent both episodic and chronic migraines and has approved IntelGenx’s Rizafilm for treatment of acute migraine.

Qulipta, a once-a-day oral treatment previously indicated to prevent episodic migraine, is now available for chronic migraines, defined as headaches for 15 or more days per month, with at least eight of those days associated with migraine.

Rizafilm is an oral thin film formulation of rizatriptan benzoate, which is “well-suited to the approximately 80 percent of patients who have migraine-related nausea, as well as those who have difficulty swallowing” during an acute migraine event, the company said.;

Related Topics